Hvivo sees revenue jump 30% to £50.6 million on back of bigger contracts

Hvivo, formerly known as Open Orphan, has reported a 30 per cent jump in revenue to £50.6 million (€57.2 million) for last year. The Dublin and London-listed pharmaceutical company said bigger contracts with clients drove the size of its order book to £76 million by the end of last year, up 65 per cent on 2021 and six times what it was in 2020.

In a trading update on Tuesday, it forecast revenue for this year would rise further to £55 million

As of December 31st last, the group’s cash position was £28.4 million, up from £15.7 million in 2021. Hvivo said EBITDA (earnings before interest tax depreciation and amortisation) margins were 17.9 per cent, ahead of previous guidance and up from 7.4 per cent in 2021.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    hVIVO enters 2024 with 90% of revenue guidance already contracted

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced an unaudited trading update for the year ended 31 December 2023. Highlights • Full year revenue of £56.0 million,

    hVIVO plc

    A day in the life of a Laboratory Team Leader at hVIVO

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical

    hVIVO plc

    Companies to follow in 2024: hVIVO

    Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas

    hVIVO plc

    FluCamp 2023: Year in Review

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical

    hVIVO plc

    Irish-listed Hvivo signs €7.3m contract with biotechnology firm

    Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client. Irish-founded Hvivo runs drug trials known as challenge studies from its London clinics. The company will test the biotechnology’s client’s antiviral candidate

    hVIVO plc

    hVIVO appoints Nominated Adviser and Joint Broker

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as